Epigenomics News and Research

RSS

Cancer Genomics now available online

Genome Research publishes online and in print today a special issue entitled, "Cancer Genomics," highlighting insights gained form cutting-edge genomic and epigenomic analyses of cancer.

2 Feb 2012

Genomatix is among the 41 partners of BLUEPRINT epigenome consortium

Genomatix is among the 41 partners of the BLUEPRINT epigenome consortium funded by the European Commission as a high impact project within its seventh framework program.

18 Oct 2011

NanoString introduces nCounter Analysis System

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of its second generation nCounter Analysis System.

From Nanostring 13 Oct 2011

Johns Hopkins establishes Center for Personalized Cancer Medicine with Commonwealth Foundation gift

A $30 million gift from the Commonwealth Foundation for Cancer Research has enabled the Johns Hopkins Kimmel Cancer Center to establish a Center for Personalized Cancer Medicine. The gift from the Richmond, VA- based foundation, will be used to support research and the development of new technologies that pinpoint the novel genetic characteristics of each patient's cancer.

22 Aug 2011

Blood tests encourage more people to participate in regular screening for colorectal cancer

Epigenomics AG, the cancer molecular diagnostics company, today announced the results of a survey conducted at europacolon's first European CRC Patient Conference, The Power of Patient Voice 2011, showing that patients believe tests using blood samples would encourage more people to participate in regular screening for colorectal cancer.

8 Jul 2011

Epigenomics presents Septin9 blood test study data in colorectal cancer at DDW 2011

Epigenomics AG, the cancer molecular diagnostics company, reports that Dr. Uri Ladabaum, Associate Professor in the Department of Gastroenterology and Hepatology at the School of Medicine of Stanford University, has presented the results of a health economic analysis of potential future colorectal cancer screening with Septin9 blood tests at the ongoing Digestive Disease Week 2011.

9 May 2011

Epigenomics, Life Technologies enter supply agreement for second-generation colorectal cancer blood test

Epigenomics AG, the cancer molecular diagnosis company, today announced the signing of a supply agreement with Life Technologies Corporation, a global provider of innovative life science solutions.

7 May 2011

Quest Diagnostics ColoVantage molecular colorectal cancer detection test receives New York State approval

Quest Diagnostics Incorporated, the world's leading cancer diagnostics company, today announced that its ColoVantage test has been approved by New York State's Department of Health for testing on samples of patients in the state. It is believed to be the first molecular colorectal cancer detection method that employs a venal blood specimen to be approved by the state.

From Quest Diagnostics 18 Mar 2011

QIAGEN, Epigenomics enter option agreement to commercialize colorectal cancer blood test

Epigenomics AG, the cancer molecular diagnostics company, and QIAGEN today announced that the companies have entered into an option agreement allowing QIAGEN to develop and, should QIAGEN exercise the option, commercialize a colorectal cancer blood test based on Epigenomics' proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies.

From Qiagen 28 Feb 2011

CLC bio releases Version 4.5 of CLC Genomics Workbench

Today, CLC bio announced the release of CLC bio's premier desktop software package for working with genomics, transcriptomics, and epigenomics: Version 4.5 of CLC Genomics Workbench - an update which gives molecular biologists access to analyze high-througput sequencing datasets with powerful bioinformatics algorithms through a user-friendly graphical user-interface.

4 Feb 2011

Epigenomics concludes feasibility phase in development of improved product concept for Epi proColon

Epigenomics AG, the cancer molecular diagnostic company, today announced that it has concluded the feasibility phase in the development of an improved product concept for Epi proColon, the Company's DNA methylation-based blood test for assistance in the detection of individuals with colorectal cancer.

13 Jan 2011

New findings on folic acid supplementation reveal causes of low birth weight

Groundbreaking work by a team of UK scientists has identified, for the first time, a link between changes in the DNA of newborn babies, folic acid supplementation during pregnancy, and birth weight.

1 Dec 2010

Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer

Epigenomics AG , the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced that they have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009.

17 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Douglas C. Wallace, Ph.D., a pioneer and internationally prominent scientist in the field of human mitochondrial genetics, has joined The Children's Hospital of Philadelphia to continue his investigations into the role of mitochondrial energy in health and disease.

29 Oct 2010

Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW

Epigenomics AG, the cancer diagnostics company, announced that new data obtained in a clinical study with the Company's proprietary Septin9 biomarker for the blood-based detection of colorectal cancer, were presented yesterday at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain.

28 Oct 2010

Einstein updates Strategic Research Plan

Albert Einstein College of Medicine of Yeshiva University has updated its Strategic Research Plan, the guidepost by which research priorities for the College of Medicine are set and measured. The update is designed to keep Einstein's research enterprise on course, to determine which investigative areas should be expanded or redirected, and to identify new areas that were underappreciated when the original research plan was formulated.

26 Oct 2010